Centering discussion on patient profiles, expert panelists review recent advances in the treatment of renal cell carcinoma and their impact on clinical practice.
March 18th 2022
Experts review a clinical scenario of intermediate- and poor-risk renal cell carcinoma that is managed with ipilimumab-nivolumab and nivolumab maintenance.
Focusing on immunotherapy in the setting of intermediate- and poor-risk renal cell carcinoma, panelists review toxicity management and duration of response.
March 25th 2022
A brief discussion on triplet therapy being investigated in patients with intermediate- and poor-risk renal cell carcinoma.
A second clinical scenario focusing on favorable-risk renal cell carcinoma managed with lenvatinib-pembrolizumab therapy.
April 1st 2022
Shared insight on the patient and disease factors that inform the selection of therapy for favorable-risk renal cell carcinoma.
Expert perspectives on lenvatinib/pembrolizumab combination therapy in renal cell carcinoma, including appropriate dosing and adverse event management.
April 8th 2022
A clinical scenario of renal cell carcinoma treated with surgery and adjuvant pembrolizumab is reviewed by a panel of experts.
Expert perspectives on the possible roles of neoadjuvant nivolumab and adjuvant sunitinib for patients with renal cell carcinoma.
April 15th 2022
A brief discussion on the genetic risk tied to clear cell renal cell carcinoma and how that may inform familial risk and testing.
Experts review a clinical scenario of non–clear cell renal cell carcinoma, wherein the patient is managed with cabozantinib-nivolumab.